Source: Fortune
Summary
The FDA approved Rasonque, a drug developed by Revolution Medicines, to treat metastatic pancreatic cancer by targeting RAS mutations. The drug, which showed a median survival of 13.2 months compared to 6.7 months on standard chemotherapy, was fast-tracked and received Breakthrough Therapy and Orphan Drug designations. The approval comes as pancreatic cancer remains one of the deadliest, with a five-year survival rate of just 13%. Investors and oncologists see the drug as a major breakthrough, with potential for off-label use in other cancers.
Our Reading
The numbers tell one story.
Revolution Medicines got fast approval for Rasonque, a drug targeting RAS mutations in pancreatic cancer.
The FDA moved quickly, aided by international collaboration and the drug’s strong trial results.
Patients on Rasonque lived nearly double the time of those on standard chemo.
The drug’s success in pancreatic cancer, a tough case, signals broader potential for RAS-targeting therapies.
Author: Evan Null
Fast-Tracked FDA Approval
The FDA approved Rasonque in 6.5 months, well ahead of its deadline, thanks to new rules allowing international regulators to review oncology applications alongside the agency. The drug was fast-tracked due to its significant results in a high-unmet-need area, according to Angelo de Claro, director of the FDA’s Oncology Center of Excellence.
Significant Trial Results
In the trial, patients taking Rasonque lived a median of 13.2 months, compared to 6.7 months on standard chemotherapy. The drug reduced the risk of death by 60% and improved quality of life measures. These results positioned Rasonque as a major advance in treating pancreatic cancer, a disease with a notoriously low survival rate.
Revolution Medicines’ Platform
Rasonque is part of a broader platform developed by Revolution Medicines to target RAS mutations, which appear in about a quarter of all human cancers. The company is also testing daraxonrasib in late-stage lung cancer trials, indicating a strategic expansion beyond pancreatic cancer.
Pricing and Access
Revolution Medicines set a list price of $39,800 for a 30-day supply of Rasonque, but eligible insured patients can pay as little as $0 through a support program. An expanded access program launched in May has already reached over 2,000 patients, showing early adoption and demand.
Investor and Expert Reactions
Dr. Danish Nagda, an early investor in Revolution Medicines, called the approval a major milestone, highlighting the drug’s potential beyond pancreatic cancer. He compared Rasonque’s mechanism to turning off a cancer switch and predicted significant off-label use. Nagda also drew a contrast with mRNA cancer vaccines, suggesting a future of combination therapies that could transform cancer treatment.
